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Curcuma aromatica is a plant belonging to genus Curcuma of family Zingiberaceae and is widely used as supplements in Japan.
Rhizomes of C. aromatica have curcumin as a major yellow pigment and curdione as a main ingredient of essential oils. In this
study, we investigated the aﬀect of C. aromatica on CYP3A4 using 1α,25-(OH)2-D3-treated Caco-2 clone cells. Caco-2 cells were
treatedwithmethanolextract(0.1mgml−1),itshexane solublefraction(0.1mgml−1),curcumin(4μM)andcurdione(20μM) for
72 hours. Nifedipine was used as a substrate of CYP3A4. Methanol extract, hexane fraction and curdione inhibited the formation
of oxidized nifedipine by 50–70%, and curcumin showed no eﬀect. The IC50s of methanol extract, hexane fraction and curdione
to oxidized nifedipine formation were 21, 14 and 3.9μgml −1 (16.9μM), respectively. The content of curdione in methanol extract
was 11.4%. Moreover, all of methanol extract, hexane fraction and curdione decreased CYP3A4 protein expression but had no
aﬀect on CYP3A4 mRNA expression. Our results showed that these drugs further decreased the CYP3A4 protein expression level
after the protein synthesis was inhibited by cychroheximide. These ﬁndings suggest that curdione plays an important role in the
CYP3A4 inhibitory activity of C. aromatica and curdione might inhibit the activity by accelerating the degradation of CYP3A4.
1.Introduction
Curcuma aromatica (also called Haruukon in Japanese) is
a plant belonging to the genus Curcuma of family Zingib-
eraceae. In Japan, C. aromatica is called Spring Curcuma
because it is in bloom in April/May and C. longa is called
Autumn Curcuma because it is in bloom in July/August.
Traditionally, C. longa is recommended to improve hepatica
function and C. aromatica is administrated to people with
gastrointestinal dysfunction. In present, both C. aromat-
ica and C. longa are used as supplements because of
theirvariouspharmacologicalactivitiesincludingpromotion
of blood circulation, anti-cancer and anti-inﬂammation
[1, 2]. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione; Figure 1) is a yellow pigment from C.
aromatica and C. longa.I th a sb e e nr e p o r t e dt h a tc u r c u m i n
possesses wide range of pharmacological activities and is
widely used, especially as a cancer chemopreventive agent [3,
4]. Salvioli et al. [5] discussed the multitudinous biological
mechanisms and possible clinical eﬀects of curcumin and
put forward a xenohormetic mechanism. Normally, the
content of curcumin in C. longa is about 10-fold of that
of C. aromatica. On the other hand, C. aromatica has
much more essential oil components than C. longa [6].
Some essential oil components, such as β-bisabolene, β-
sesquiphellandrene and ar-curcumene have been reported
and it was showed that these essential oils exhibited multiple
biological activities [7, 8]. Recent research further indicated
the chemoprotective eﬀects of C. aromatica oil on esophageal
carcinogenesis [9]. Curdione (Figure 1)o fg e r m a c r o n et y p e
is a main ingredient of the essential oils [10]. Recently,
Oh et al. [11] indicated that curdione may be a can-
didate for anti-inﬂammatory and cancer chemopreventive
agents.2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Chemical structure of curcumin and curdione.
As herbal medicinal products have become prevalent
throughouttheworld,thefatalnessofherb-druginteractions
stands out [12, 13]. Cytochrome P450 (CYP) 3A4 enzyme
is the most abundant in human cytochromes. It accounts
for up to 30–40% of gastrointestinal CYPs and 50% of
intestinal CYPs content. Moreover, CYP3A4 is responsible
for the metabolism of ∼60% of the drugs in current clinical
use [14]. Many herbal drugs have been reported as CYP3A4
inducer/inhibitor [15]. Some clinical trials also showed
that various herbal products can aﬀect the metabolism of
drugs which are CYP3A4 substrate [16, 17]. The inhibi-
tion/induction of CYP3A4 has been reported as a signiﬁcant
reason for herb-drug interaction [18].
The Caco-2 cell model is a well-established model to
study the absorption and related mechanism of drugs [19–
21]. Schmiedlin-Ren et al. [22] showed that expression of
CYP3A4 in Caco-2 cells was up-regulated by 1-alpha, 25
dihydroxyvitamin D3 (1α,25-(OH)2-D3) treatment, and that
these cells might be a promising model to simulate the
absorption and metabolism of small intestine. Following
that, some researches had veriﬁed the activity level of
CYP3A4 in the modiﬁed Caco-2 cells and showed that
the expression and activity of CYP3A4 were inhibited by
grapefruit juice [23–25]. This modiﬁed cell has become an
accepted tool to detect inhibition/induction of CYP3A4. In
another of our study, we reported the CYP3A4 inhibitory
activity of C. longa a n dc u r c u m i n[ 26]. The present study
was conducted to evaluate the eﬀect of C. aromatica on
CYP3A4, and to identify CYP3A4-inhibiting components in
C. aromatica. In addition, eﬀorts were tried to clarify the
CYP3A4-inhibiting mechanism.
2. Methods
2.1. Materials and Chemicals. Caco-2 cells (HTB37) were
obtained at passage 18 from American Type Culture Col-
lection (Manassas, VA). Caco-2 cell clone P27.7 was a
genourous gift from Dr. Paul B. Watkins. Curcuma aromatica
rhizomesproducedfromOkinawapref.werepurchasedfrom
Nakazen Co., Ltd. (Okinawa, Japan) and correctly identiﬁed
by the molecular biological method previously reported
[27]. This drug sample is preserved with specimen reference
number 25343 in the Museum of Materia Medica, Institute
ofNaturalMedicine,UniversityofToyama,Japan.Curcumin
was isolated from the methanol extract of C. longa rhizomes
by column chromatography and preparative TLC, and cur-
dione was isolated from the methanol extract of C. aromatica
rhizomes by preparative HPLC. The isolated compounds
were identiﬁed by comparison of NMR and mass spectral
data with those reported [28]. Cychloheximide (CHX), non-
essential amino acids (NEAA), antibiotic-antimycotic mixed
stock solution, glucose, dl-α-tocopherol, sodium selenite,
zinc sulfate, ferrous sulfate, ethlenediaminertetracetic acid
(EDTA) and trypsin were obtained from Nacalai Tesque
(Kyoto, Japan). Fetal bovine serum (FBS) was from Biowest,
Inc. (Nuaiill´ e, France). Testosterone, 6β-OH testosterone,
nifedipine and oxidized nifedipine were purchased from
SigmaChemicalCo.(St.Louis,MO,USA).Dulbelcco’smod-
iﬁed Eagle’s medium (DMEM), 1α, 25-(OH)2-D3 were from
WakoPureChemicalIndustries.Transwellpolycarbonatecell
cultureinserts(24mmdiameter,0.4μMporesize)werefrom
Costar Corp. (Bedford, MA, USA). Millicell ERS device was
obtainedfromMillipore(Bedford,MA,USA).Stocksolution
of the methanol extract of C. aromatica and its hexane
soluble fraction, curcumin and curdione were prepared at
50mgml−1 a n d1 0 0m Mi nD M S Oa n ds t o r e di n−20◦C.
2.2. Cell Culture Conditions. Caco-2 cells at passages 24–27
and Caco-2 clone cells at passages 24–30 were used for all
experiments. Cell cultures were maintained in a humidiﬁed
37◦C incubator with 5% carbon dioxide in air atmosphere.
Caco-2 cells were grown in plastic tissue culture dishes in
a maintenance medium consisting of DMEM containing
25mM glucose, 4mM l-glutamine, 0.1mM nonessential
amino acids, 100unitsml−1 penicillin, 100unitsml−1 strep-
tomycin, 250nM amphotericin and supplemented with
10% heat-inactivated FBS. When the cells reached 80%
conﬂuence, they were removed using 0.2% trypsin/EDTA,
diluted with 1 : 4 and reseeded onto fresh tissue culture
dishes. The medium was changed at an interval of 2-3 days.
2.3. Preparation of Methanol Extract and Hexane Fraction.
Curcuma aromatica rhizome was pulverized and 10g of the
powder was extracted with 150ml of methanol under reﬂux
conditions for 3 hours. The organic solvent was evaporated
in vacuo to give an extract. Of the extract, 567mg was
dissolvedin30mlofmethanolandextractedthreetimeswith
30ml of hexane to separate the methanol extract into hexane
and methanol soluble fractions (164 and 282mg, resp.). TheEvidence-Based Complementary and Alternative Medicine 3
curcumin content of the methanol extract was analyzed as
previously described [26].
2.4. GC-MS Analysis. Curdione contents of the methanol
extract and hexane fraction were analyzed using a Shimadzu
GC-17A gas chromatograph interfaced with a Shimadzu QP-
5000 quadrupole mass spectrometer (Shimadzu Co., Kyoto,
Japan). The GC/MS system was operated with an interface
temperature of 280◦C and an ion source temperature of
280◦C. EI mass spectra were obtained at an ionizing energy
of 70eV and eission current of 60μA. Chromatographic sep-
aration was achieved using a DB-1MS fused-silica capillary
column (30 m × 0.25mm i.d., ﬁlm thickness 0.1μm; J&W
Scientiﬁc, Folsom, CA, USA). Helium was used as a carrier
gas at a ﬂow rate of 1mlmin−1. An AOC-20i autoinjector
(Shimadzu Co.) was used to inject 2μl of standard solu-
tion, extract or fraction into the GC/MS system. The gas
chromatograph was equipped with a split/splitless injection
port operated at 260◦C. The samples were injected in the
split mode (split ratio 1 : 20). The GC oven temperature
was initially held at 100◦Cf o r2m i na n dt h e nt e m p e r a t u r e -
programmed at 10◦Cm i n −1 to 280◦C.
2.5. Three-Dimensional HPLC Analysis. The methanol
extract and hexane fraction were dissolved in methanol and
then submitted for HPLC analysis with a Shimadzu LC-20A
system equipped with a Shimadzu SPD M10A photodiode
array detector. A Waters Symmetry C18 column (150mm
× 4.6mm i.d., 5μm) was used. The column temperature
was set at 40◦C and eluted compounds were detected by
monitoring at 200–500 nm. The mobile phase was a binary
eluent of (A) 5mM ammonium acetate solution (pH 3.6),
(B) CH3CN under following gradient conditions: 0–30 min
linear gradient from 10 to 100% B, 30–40 min isocratic at
100% B. The ﬂow rate was 1mlmin−1.
2.6. CellTiter 96 Aqueous Cell Proliferation Assay (Promega).
The cytotoxicity of methanol extract, hexane fraction and
curdione on Caco-2 clone cell proliferation was deter-
mined using CellTiter 96 aqueous one solution reagent
(Promega Corporation). Caco-2 cells at a concentration of
105 cellscm−2 were seeded in 96-well plates. After the cells
had reached 80–90% conﬂuence, they were treated with 0–
0.5mgml−1 extract/fraction or 0–500μM curdione for 72
hours. Following removal of the drugs, cells were washed
with phosphate-buﬀered saline (PBS). The cells were then
incubated in the serum-free maintenance medium (100μl)
with one solution reagent (20μl) for a further 4 hours.
Viability was deﬁned as the ratio (expressed as a percentage)
of absorbance of treated cells to untreated cells at 490 nm.
2.7. 1α,25-(OH)2-D3 Treatment. Caco-2 cells were seeded
at 5×105 cellscm−2 onto the culture insert and cultured
in complete growth medium, which was prepared based
on the maintenance medium supplied with 45nM dl-α-
tocopherol and 20% heat-inactived FBS. After 10 days,
the medium was additionally supplemented with sodium
selenite (0.1μM), zinc sulfate (3nM), ferrous sulfate (5μM)
and 1α,25-(OH)2-D3 (250nM). Simultaneously, the content
of FBS was decreased to 5%. Cells were incubated for further
3w e e k s .
2.8. Monolayer Integrity. Cell monolayer integrity was evalu-
ated with transepithelial electrical resistance (TEER). Resis-
tance was measured using a Millicell-ERS resistance system
afterthemediumwaschanged.Aninsertthatdidnotcontain
cellswasusedasbackgroundresistance.TEERwascalculated
from the background-corrected resistance and the surface
area of the insert (4.76cm2).
2.9. Inhibition of CYP3A4 Catalytic Activity. After treated
with 1α,25-(OH)2-D3 for 3 weeks, extract/fraction, cur-
cumin or curdione was added to the apical compartment
and the incubation lasted for 72 hours. After the medium
was aspirated, the monolayers were washed with the warm
EBSS buﬀer twice. The EBSS buﬀer containing nifedipine
(200μM) was added to the apical compartment. After
incubating the cells at 37◦C for 4 hours, basolateral (2.6ml)
m e d i aw a sc o l l e c t e da n ds t o r e da t−80◦C for analysis.
2.10. Analysis of Oxidized Nifedipine by HPLC. Ethylacetate
(EtOAc, 3ml) was added to media (1ml) in an amber vial.
Then, the content of each vial was mixed using a vortex
device and the two layers were separated by centrifugation
at 1500g for 10 min. From each upper organic layer, 2.5ml
was transferred to another amber vial and dried using a
centrifugation evaporator. The content was dissolved in
200μlofeluate(MeOH:H2O =55:45)and50μlwasinjected
to the HPLC system. The reversed-phase separation was
performed in Inertsil ODS-3 column (150mm × 4.6mm
i.d., 5μm particles, GL Sciences Inc., Japan). Elution was
performed at a rate of 1mlmin−1 and monitored at 254 nm.
Standards of oxidized nifedipine were made in methanol.
Concentrations were obtained by extrapolation of the peak
area from a standard curve.
2.11. Cell Lysis. Cell monolayers were washed with cold PBS
for three times. Total cellular proteins were extracted in
the lysis buﬀer containing 150mM NaCl, 10mM Tris (pH
7.4), 1mM EDTA, 1% Triton X-100, 1% deoxycholic acid
and protease inhibitor mixture. Protein concentrations were
determined by the BCA protein assay reagent kit (Sigma-
Aldrich), using bovine serum albumin as a standard. Total
cell lysate was stored at −80◦C for analysis.
2.12. Western Blot Analysis. Proteins (12μg) from the total
cell lysate were analyzed by SDS–PAGE (12.5% gel). After
blotting, the PVDF transfer membrane (Amersham Bio-
sciences) was blocked with 5% skimmed milk in PBS with
Tween 20 at room temperature for 1 hour. Immunoblots
were incubated at room temperature for 1 hour with the
speciﬁcprimaryantibodytoCYP3A4(BDBiosciences).After
further washing, the membranes were incubated for 1 hour
with the secondary antibody (Santa Cruz Biotechnology).
Blots were reprobed with antibody to GAPDH as a loading
control. Quantitative analysis of immunoblotted bands was4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Induction of CYP3A4activity and protein expression by 1α,25-(OH)2-D3. Caco-2 clone cells grown on culture inserts were treated
with1α,25-(OH)2-D3 (250nM)for3weeksafterconﬂuence.(a)Metabolicactivityof1α,25-(OH)2-D3-treatedCaco-2clonecells.Nifedipine
(200μM) was added to the apical compartment. After 4 hours, basolateral media was collected and analyzed for oxidized nifedipine. Results
are means ± SD from triplicate experiments. ∗∗P < .01 versus control. (b) CYP3A4 expression level of 1α,25-(OH)2-D3-induced Caco-2
clone cells.
performed by a computer program (NIH Image, version
1.61).
2.13. RNA Extraction and SYBR GREEN I Real-Time PCR.
The total RNA was extracted from the treated cells using
TRIzol reagent (QIAGEN). First strand cDNA was generated
from 1μg of total RNA by the oligo(dT) ﬁrst strand
primer (Invitrogen). Real-time PCR was performed with
50 000 fold diluted SYBR GREEN I dye (Invitrogen). For
CYP3A4, the forward primer sequence used was 5 -ACT-
GAGTCCCACAAAGCTCTGTC-3  and the reverse primer
sequence used was 5 -AACTGCATCAATTTCCTCCTGC-
3 ;f o rβ-actin, the forward primer sequence used was 5 -
GGTCATCACCATTGGCAATGA-3  and the reverse primer
sequence used was 5 -GTAGTTTCGTGGATGCCACAGG-
3 . Aliquots of the reverse-transcription reaction mixture
(1μl) were ampliﬁed and detected using a ABI PRISM 7000
Sequence Detector System (Applied Biosystems) with the
following proﬁle: 1 cycle of 50◦Cf o r2m i n ,1c y c l eo f9 5 ◦C
for 5 min and 45 cycles each of 95◦C for 15 s and 60◦Cf o r1
min. The CYP3A4 mRNA levels were normalized relative to
the β-actin mRNA level in each sample.
2.14. Statistics. Experiments were repeated for at least three
times, and data were expressed as means ± standard
deviation (SD). Statistical signiﬁcances between treatment
groups were determined using Student’s t-test or ANOVA
and Scheﬀe’s test. Treatment was considered signiﬁcantly
diﬀerent from controls if P < .05.
3. Results
3.1. Induction of the CYP3A4 Activity of Caco-2 Clone
Cells by 1α,25-(OH)2-D3. Caco-2 cells from ATCC were
incubated for 4 weeks without 1α,25-(OH)2-D3 treatment.
Then nifedipine was ultilized to detect the metabolic activity
of CYP3A4 [29]. Our pre-experiment indicated that the for-
mationofoxidizednifedipinebyCYP3A4inCaco-2cellswas
correlated with the concentration of nifedipine added in the
apical compartment when the concentration of nifedipine
was below 200μM. Thus, in our experiment, nifedipine with
a concentration of 200μM was used. Nifedipine (200μM)
was added to the apical compartment and little oxidized
nifedipine was detected in the basolateral side after incuba-
tion for 4 hours. As shown in Figure 2, Caco-2 clone cells
showed about 6-fold higher metabolic activity of nifedipine
than Caco-2 cells. Furthermore, treatment with 1α,25-
(OH)2-D3 for 3 weeks increased the nifedipine metabolic
activity of Caco-2 clone cells for about 10-fold and oxidized
nifedipine was detected in the basolateral compartment as
a concentration of 4.6 ± 1.3μM. The metabolic activity of
1α,25-(OH)2-D3-treated Caco-2 clone cells was induced by
∼60-fold compared to that of ATCC Caco-2 cells. Moreover,
the induction of CYP3A4 protein expression in Caco-2
clone cells was also proved by western blot. The metabolic
activity of nifedipine kept stable among diﬀerent passages
of Caco-2 clone cells used in the experiments. Experiments
were conducted on monolayers with transepithelial electrical
resistance (TEER) of >400Ωcm2.
3.2. Methanol Extract, Hexane Fraction, Curcumin and Cur-
dione Inhibited Nifedipine Oxidization in 1α,25-(OH)2-D3-
Treated Caco-2 Clone Cells. After treatment for 72 hours,
both methanol extract and hexane fraction inhibited cell
growth in a concentration-dependent way. They showed
no cytotoxicity to Caco-2 cells when the concentration was
<0.1mgml−1. The 50% cytotoxicity concentrations (CC50)
of methanol extract and hexane fraction were 0.26 and
0.22mgml−1,respectively.TheCC50ofcurcuminwas73μMEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Inhibition of nifedipine oxidation by components
from C. aromatica (MeOH extract: 0.1mgml−1; haxane fraction:
0.1mgml−1; curdione: 20μM; curcumin: 4μM). Components were
applied to the apical compartment and incubated for 72 hours.
After removing components, nifedipine (200μM) was added to the
apical compartment and incubated for 4 hours. The amount of
oxidized nifedipine in the basolateral compartment was measured.
Results are means ± SD from triplicate experiments. ∗∗P < .01
versus control.
(0.027mgml−1). On the other hand, curdione showed no
cytotoxicity to Caco-2 clone cells even when the concentra-
t i o nw a sa sh i g ha s5 0 0μM (0.1182mgml−1).
A f t e rC a c o - 2c l o n ec e l l sw e r et r e a t e dw i t ha l ld r u g sf o r
72 hours, there were no signiﬁcant changes in TEER. In this
study, Caco-2 cells were treated with drugs with various con-
centrations to calculate the IC50. Then some concentrations
without cytotoxicity were picked out for further experiment
as follows: methanol extract: 0.1mgml−1; hexane fraction:
0.1mgml−1; curdione: 20μM (0.0047mgml−1); curcumin:
4μM (0.0015mgml−1). In 0.1mgml−1 of methanol extract,
the curcumin concentration is 4μM since it occupied 1.2%
of the methanol extract in content, and the curdione
concentration is ∼40μM because it occupied 11.4% of
the methanol extract. Because of the strong inhibitory
activity of curdione on oxidized nifedipine formation, half
of the curdione concentration in methanol extract was
picked out as 20μM. The results were indicated in Figure 3.
The amount of oxidized nifedipine formed by methanol
extract-treated Caco-2 monolayer was ∼32% of that of the
control monolayer, and just ∼23% of oxidized nifedipine
was detected in the hexane fraction treated well compared
to that in the control well. Curdione (20μM) also inhibited
∼60% of oxidized nifedipine formation. Curcumin (4μM)
showed no signiﬁcant inhibitory eﬀects on the metabolism
ofnifedipine. 3D-HPLCchromatogramsofmethanolextract
Table 1: Relationship between CYP3A4 inhibitory activity and
content in MeOH extract.
IC50 (μg/ml) Content (%)
MeOH extract 21 ± 1.8 —
Hexane fraction 14 ± 2.6 (11.3(a)) 54.0
Curdion 3.9 ± 1.7 (2.4(a)) 11.4
Curcumin >11.1 1.2
(a)Theoritical value calculated from the content in MeOH extract hypoth-
esizing that curdion is the only component responsible for the CYP3A4
inhibitory activity of C. aromatica when the IC50 of MeOH extract is
21μg/ml. Results are means ± SD from triplicate experiments.
and hexane fraction were shown in Figure 4. The result
indicated that almost all curdione content in methanol
extract was fractionated by hexane. The IC50 of hexane
fraction to nifedipine oxidization was 14μgml −1,w h i c hi s
∼67% of the value for methanol extract. The content in
methanol extract and IC50 of curdione were 11.4% and
3.9μgml −1 (16.86μM), respectively. On the other hand,
IC50 of curcumin was >11.1μgml −1 (30μM) (Table 1).
3.3. Methanol Extract, Hexane Fraction, Curcumin and
Curdione Decreased the Expression Level of CYP3A4 Protein
but Had No Eﬀect on the Expression of CYP3A4 mRNA in
1α,25-(OH)2-D3-Treated Caco-2 Clone Cells. To clarify the
CYP3A4 inhibitory mechanism of methanol extract, hexane
fraction, curcumin and curdione, western blot and real-time
PCR were carried out (Figure 5). When Caco-2 clone cells
were treated with methanol extract, hexane fraction and
curdione for 72 hours, the CYP3A4 protein expression was
decreased signiﬁcantly to 30–50% compared with that of
the control group. Curcumin treatment showed no aﬀect on
CYP3A4 protein expression. On the other hand, no change
was found in the CYP3A4 mRNA expression levels when
Caco-2 clone cells were treated with any of them.
After 1α,25-(OH)2-D3 treatment, CHX (10μgml −1)w a s
added to Caco-2 clone cells. After 1 hour, methanol extract
(0.1mgml−1), hexane fraction (0.1mgml−1) and curdione
(20μM) were added and the treatment lasted for 24 hours.
Western blot was used to evaluate the variation of the
CYP3A4 protein expression level. Compared to the control
group which is treated just with CHX, all of methanol
extract, hexane fraction and curdione treatment decreased
the protein expression of CYP3A4 by 30–60% (Figure 6).
4. Discussion
Curcuma species (C. longa, C. zedoaria and C. aromatica)
are used as traditional medicines and supplements in East
Asia. In the past, Curcumas were recommended as botanical
supplements and traditional herbs with a high rank. It was
thought that Curcumas would not lead to any side-eﬀect
even when they were administrated with a very large dose.
However, since 1996, case reports appeared and showed
that Curcumas administration had caused some side-eﬀect,
such as drug-induced hepatitis [30]. It became necessary
to oﬀer some information for the correct use of Curcumas.6 Evidence-Based Complementary and Alternative Medicine
Curdione
Demethoxycurcumin
Curcumin
100
−50
W
a
v
e
l
e
n
g
t
h
(
n
m
)
Retention time (min)
500
400
300
200
0
10
20
30
40
(a)
Curdione
100
−50
W
a
v
e
l
e
n
g
t
h
(
n
m
)
Retention time (min)
500
400
300
200
10
20
30
40
(b)
Figure 4: 3D-HPLC chromatogram of MeOH extract (a) and hexane fraction (b) of C. aromatica.
Nagamura et al. [31] reported that C. longa and curcumin
inhibited the function of both sulfotransferase (SULT) and
UDP-glucuronosyl transferase (UGT) activity in Caco-2
cells. In our previous report, we have described that C.
longa and C. zedoaria might inhibit the catalytic activity
of intestinal CYP3A4, and curcumin was not the major
compound responsible for this inhibitory eﬀect [28]. In
Curcuma species, C. aromatica (Haruukon in Japanese) is
a special member since there is confusion in the origin
of this crude drug and the nomenclature of this plant
is inconsistent in East Asia. In this study, C. aromatica
(Haruukon in Japanese) identiﬁed by the molecular bio-
logical method were used and we reported for the ﬁrst
time that C. aromatica might inhibit the intestinal CYP3A4
activity. Furthermore, we proved that curdione, an essential
oil from C. aromatica, played an important role in the
inhibitory activity. We even identiﬁed that curdione might
inhibit CYP3A4 activity by accelerating the degradation ofEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Eﬀects of MeOH extract, hexane fraction, curcumin and curdione on CYP3A4 protein and mRNA expression levels. Components
were applied to the apical compartment and incubated for 72 hours. Then cell lysate or total RNA was prepared for western blot or real-time
PCR. (a) Representative western immunoblot for CYP3A4 and quantitative analysis of CYP3A4 immunoprotein. The western immunoblot
band intensities were normalized with that of GAPDH. Results are means ± SD from triplicate experiments. ∗∗P < .01 versus control. (b)
Quantitative analysis of CYP3A4 mRNA. Results are means ± SD from triplicate experiments.
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Figure 6: Eﬀects of MeOH extract, hexane fraction and curdione
on CYP3A4 protein expression in CHX-treated Caco-2 cells. The
western immunoblot band intensities were normalized with that of
GAPDH. Results are means ± SD from triplicate experiments. ∗∗P
< .01 versus control.
CYP3A4 protein. To our knowledge, this is the ﬁrst of these
reports.
Almost all herbs are administrated orally. The ﬁrst major
barrier for them to cross is the intestinal epithelium. In
our previous study, 1α,25-(OH)2-D3-modiﬁed Caco-2 cells
had been used to mimic the absorption and metabolism
of small intestine since this system showed ample CYP3A4
metabolic activity. However, we found that sometimes the
CYP3A4 activity level was labile among diﬀerent Caco-2
monolayers although we had tried to keep the incubation
condition identical. To obtain genetic homogeneity among
the cells, Caco-2 clone cells (P27.7) were employed in these
experiments instead of normal Caco-2 cells. Schmiedlin-Ren
et al. [22] reported that the midazolam 1 -hydroxylation
rate was 75.9pmolmin−1 g−1 of cells when the clone cells
were treated with 250nM 1α,25-(OH)2-D3 for 2 weeks.
Some researches reported that the CYP3A4 activity can be
improved by ∼100-fold in CYP3A4-transfected Caco-2 cells
[32, 33]. However, there is limitation in these cells when
they are utilized to clarify the mechanism of herb-drug
interaction. In our experiment, we proved that the Caco-
2 clone cells had a relatively high level of CYP3A4 activity
compared to our previously used Caco-2 cells, and that
1α,25-(OH)2-D3 treatment would signiﬁcantly increase the
CYP3A4 activity when nifedipine was used as a substrate.
Mostimportantly,theCYP3A4activityofourclonecellskept
stable during our experiments.
Using 1α,25-(OH)2-D3-treated Caco-2 clone cells, we
found that the metabolic activity and protein expression
of CYP3A4 were markedly inhibited when the cells were
treated with 0.1mgml−1 methanol extract of C. aromatica
for 72 hours. Our result showed that 4μMc u r c u m i n8 Evidence-Based Complementary and Alternative Medicine
had no inhibitory aﬀect on CYP3A4 metabolic activity.
Curcumin had no relation with the CYP3A4 inhibitory
activity of C. aromatica. Similarly, although some papers
reported that curcumin might inhibit the metabolic activity
of CYP3A, the eﬀect was very weak [34–36]. Price et
al. reported that the IC50 of curcumin was 29μM when
curcumin was directly added to human liver microsome.
Besides curcumin, some essential oils have been isolated
from C. aromatica. A hexane fraction, which occupied
49% of the methanol extract content, showed ∼2-fold
stronger inhibitory activity to CYP3A4 activity compared
to methanol extract. Furthermore, we found that curdione,
which occupied 11.4% of the methanol extract, signiﬁcantly
inhibited the activity of CYP3A4 with IC50 as 3.9μgml −1.
Theoretically, if curdione was the sole component that was
responsible for the CYP3A4 inhibitory activity, its IC50
should be ∼2.4μgml −1, since the IC50 of methanol extract
was21μgml −1.TherelationshipbetweenCYP3A4inhibitory
activity and content in the MeOH extract of each drugs is
summarized in Table 1. Possibly, it is curdione that inhibits
the CYP3A4 activity in methanol extract. Furanocomarins
as mediators of the interaction of grapefruit juice and
the model CYP3A4 substrate using furanocoumarin-free
grapefruit juice have been established [37]. Further study
might become necessary to verify the key role of curdione in
the CYP3A4 inhibitory eﬀect of C. aromatica using a similar
idea.
The decreased Caco-2 CYP3A4 protein levels observed
after C. aromatica treatment implied that the interaction
was not simple competitive inhibition. Same as C. longa
and C. zedoaria, C. aromatica treatment did not decrease
the expression level of CYP3A4 mRNA. Curdione showed
the same CYP3A4 inhibitory eﬀect as C. aromatica.T h e
results indicated that C. aromatica/curdione did not decrease
CYP3A4 protein content by a transcriptional way. Rather,
cychroheximide, a protein synthesis inhibitor was used to
clarify the further mechanism. In our experiment, a con-
centration as 10μgml −1 was used since it has been reported
that 98% of protein synthesis would be inhibited on this
concentration [38]. We found that C. aromatica/curdione
decreased the expression level of CYP3A4 protein at least
partially by accelerating the degradation of CYP3A4 protein.
Our results indicated that the inhibitory pattern of C.
aromatica was very similar to that of grapefruit juice, which
exhibited a mechanism-based inhibitory eﬀect on intestinal
CYP3A4. The return of CYP3A4 activity would require
de novo enzyme synthesis, which would lead to prolonged
inhibitory eﬀect.
Sharma et al. [39] reported that Curcuma extract (cur-
cuminoid: essential oil = 10:1) could be administrated safely
atdosesofupto2.2gperday.Takingthegastricﬂuidvolume
to be 1–3 l for an adult human with the body weight of 60kg
[40],theconcentrationsofCurcuma drugsinthegastricﬂuid
would be 0.7–2.2mgml−1, respectively. In Japan, the powder
of Curcuma aromatica is recommended as a supplement and
therecommendeddoserangesfrom2gperdayto5gperday.
Normally, C. aromatica has a curdione content as ∼0.65%.
Thus, the curdione in the gastric ﬂuid would be 18.3–137
4μM. It is possible for administrated Curcuma drugs and
curdione to aﬀect the pharmacokinetics of co-administrated
drugs by interfering with the intestinal CYP3A4 function.
In summary, we provide strong evidence that C. aro-
matica might inhibit the activity of intestinal CYP3A4. We
further showed that curdione, a major constituent of C.
aromatica, might be responsible for this inhibitory eﬀect.
We also indicated that curdione might inhibit the activity
of CYP3A4 by increasing its degradation. Further studies in
humans are needed to clarify the impact of this nutrient on
metabolism of orally administrated substrates of CYP3A4,
and possible other drug-metabolizing enzymes.
Funding
Mukogawa Women’s University.
References
[ 1 ]C .A .C .A r a ´ ujo and L. L. Leon, “Biological activities of
Curcuma longa L,” Memorias do Instituto Oswaldo Cruz, vol.
96, no. 5, pp. 723–728, 2001.
[2] H. Matsuda, K. Ninomiya, T. Morikawa, and M. Yoshikawa,
“Hepatoprotective, superoxide scavenging, and antioxidative
activities of aromati constituents from the bark of betula
platyphylla var japonica,” Bioorganic & Medicinal Chemistry
Letters, vol. 8, pp. 2939–2944, 1998.
[3] R. K. Maheshwari, A. K. Singh, J. Gaddipati, and R. C. Srimal,
“Multiple biological activities of curcumin: a short review,”
Life Sciences, vol. 78, no. 18, pp. 2081–2087, 2006.
[4] R. L. Thangapazham, A. Sharma, and R. K. Maheshwari,
“Multiple molecular targets in cancer chemoprevention by
curcumin,” AAPS Journal, vol. 8, no. 3, pp. E443–E449, 2006.
[5] S. Salvioli, E. Sikora, E. L. Cooper, and C. Franceschi,
“Curcumin in cell death processes: a challenge for CAM of
age-related pathologies,” Evidence-Based Complementary and
Alternative Medicine, vol. 4, no. 2, pp. 181–190, 2007.
[6] M. Minami, K. Nishio, Y. Ajioka et al., “Identiﬁcation of
Curcuma plants and curcumin content level by DNA poly-
morphisms in the trnS-trnfM intergenic spacer in chloroplast
DNA,” Journal of Natural Medicines, vol. 63, no. 1, pp. 75–79,
2009.
[7] W.Choochote,D.Chaiyasit,D.Kanjanapothietal.,“Chemical
composition and anti-mosquito potential of rhizome extract
andvolatileoilderivedfromCurcumaaromaticaagainstAedes
aegypti(Diptera:Culicidae),”JournalofVectorEcology,vol.30,
no. 2, pp. 302–309, 2005.
[8] E. Y. C. Lai, C.-C. Chyau, J.-L. Mau et al., “Antimicrobial
activity and cytotoxicity of the essential oil of Curcuma
zedoaria,” American Journal of Chinese Medicine, vol. 32, no.
2, pp. 281–290, 2004.
[9] Y. Li, J. M. Wo, Q. Liu, X. Li, and R. C. G. Martin,
“ChemoprotectiveeﬀectsofCurcuma aromatica onesophageal
carcinogenesis,” Annals of Surgical Oncology,v o l .1 6 ,n o .2 ,p p .
515–523, 2009.
[10] H. Kojima, T. Yanai, and A. Toyota, “Essential oil constituents
from Japanese and Indian Curcuma aromatica rhizomes,”
Planta Medica, vol. 64, no. 4, pp. 380–381, 1998.
[11] O.-J. Oh, H.-Y. Min, and S. K. Lee, “Inhibition of inducible
prostaglandin E2 production and cyclooxy-genase-2 expres-
sion by curdione from Curcuma zedoaria,” Archives of Phar-
macal Research, vol. 30, no. 10, pp. 1226–1239, 2007.Evidence-Based Complementary and Alternative Medicine 9
[12] E. Mills, V. Montori, D. Perri, E. Phillips, and G. Koren,
“Natural health product-HIV drug interactions: a systematic
review,” International Journal of STD and AIDS,v o l .1 6 ,n o .3 ,
pp. 181–186, 2005.
[13] A. Fugh-Berman and E. Ernst, “Herb-drug interactions:
review and assessment of report reliability,” British Journal of
Clinical Pharmacology, vol. 52, no. 5, pp. 587–595, 2001.
[14] F. P. Guengerich, “Cytochrome P-450 3A4: regulation and role
in drug metabolism,” Annual Review of Pharmacology and
Toxicology, vol. 39, pp. 1–17, 1999.
[15] F. Qiu, R. Zhang, J.Sun et al., “Inhibitoryeﬀects of seven com-
ponents of danshen extract on catalytic activity of cytochrome
P450 enzyme in human liver microsomes,” Drug Metabolism
and Disposition, vol. 36, pp. 1308–1314, 2008.
[16] L. Andr´ en, A. Andreasson, and R. Eggertsen, “Interaction
between a commercially available St. John’s wort product
(Movina) and atorvastatin in patients with hypercholes-
terolemia,” European Journal of Clinical Pharmacology, vol. 63,
pp. 913–916, 2007.
[17] B. J. Gurley, S. F. Gardner, M. A. Hubbard et al., “Clin-
ical assessment of eﬀects of botanical supplementation on
cytochrome P450 phenotypes in the elderly: St John’s Wort,
garlic oil, Panax ginseng and Ginkgo biloba,” Drugs and Aging,
vol. 22, no. 6, pp. 525–539, 2005.
[ 1 8 ]S .A .W r i g h t o n ,E .G .S c h u e t z ,K .E .T h u m m e l ,D .D .
Shen, K. R. Korzekwa, and P. B. Watkins, “The human
CYP3A subfamily: practical considerations,” Drug Metabolism
Reviews, vol. 32, no. 3-4, pp. 339–361, 2000.
[19] A. R. Hilgers, R. A. Conradi, and P. S. Burton, “Caco-2 cell
monolayers as a model for drug transport across the intestinal
mucosa,” Pharmaceutical Research, vol. 7, no. 9, pp. 902–910,
1990.
[20] W. Neuhaus, E. Bogner, M. Wirth et al., “A novel tool to
characterize paracellular transport: the APTS-dextran ladder,”
Pharmaceutical Research, vol. 23, no. 7, pp. 1491–1501, 2006.
[21] X.-L. Hou, K. Takahashi, K. Tanaka et al., “Curcuma drugs
and curcumin regulate the expression and function of P-gp
in Caco-2 cells in completely opposite ways,” International
Journal of Pharmaceutics, vol. 358, no. 1-2, pp. 224–229, 2008.
[22] P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine,
K. S. Lown, and P. B. Watkins, “Expression of enzymatically
active CYP3A4 by Caco-2 cells grown on extracellular matrix-
coatedpermeablesupportsinthepresenceof1α,25-dihydrox-
yvitaminD3,”MolecularPharmacology,vol.51,no.5,pp.741–
754, 1997.
[23] T. Aiba, M. Susa, S. Fukumori, and Y. Hashimoto, “The
eﬀects of culture conditions on CYP3A4 and MDR1 mRNA
induction by 1alpha,25-dihydroxyvitamin D(3) in human
intestinal cell lines, Caco-2 and LS180,” Drug Metabolism and
Pharmacokinetics, vol. 20, no. 4, pp. 268–274, 2005.
[24] H. Hara, Y. Yasunami, and T. Adachi, “Alteration of cellular
phosphorylation state aﬀects vitamin D receptor-mediated
CYP3A4 mRNA induction in Caco-2 cells,” Biochemical and
Biophysical Research Communications, vol. 296, pp. 182–188,
2002.
[ 2 5 ]M .F .P a i n e ,A .B .C r i s s ,a n dP .B .W a t k i n s ,“ T w om a j o r
grapefruit juice components diﬀer in time to onset of
intestinal CYP3A4 inhibition,” Journal of Pharmacology and
Experimental Therapeutics, vol. 312, no. 3, pp. 1151–1160,
2005.
[26] X. L. Hou, K. Takahashi, N. Kinoshita et al., “Possible
inhibitory mechanism of curcuma drugs on CYP3A4 in 1
alpha, 25 dihydroxyvitamin D3 treated Caco-2 cells,” Interna-
tional Journal of Pharmaceutics, vol. 337, pp. 169–177, 2007.
[27] H. Cao, Y. Sasaki, H. Fushimi, and K. Komatsu, “Molecular
analysis of medicinally-used Chinese and Japanese Curcuma
based on 18S rRNA gene and trnK gene sequences,” Biological
& Pharmaceutical Bulletin, vol. 24, pp. 1389–1394, 2001.
[28] J. Yan, G. Chen, S. Tong, Y. Feng, L. Sheng, and J. Lou,
“Preparative isolation and puriﬁcation of germacrone and
curdione from the essential oil of the rhizomes of Curcuma
wenyujin by high-speed counter-current chromatography,”
Journal of Chromatography A, vol. 1070, no. 1-2, pp. 207–210,
2005.
[29] M. Hu, Y. Li, C. M. Davitt et al., “Transport and metabolic
characyerization of Caco-2 cells expressing CYP3A4 and
CYP3A4 oxidoreductase,” Pharmaceutical Research, vol. 16,
pp. 1352–1359, 1999.
[30] R. Kumashiro, A. Hisamochi, and M. Sata, “Liver injury by
health food,” Sogo-Rinsho, vol. 55, pp. 150–151, 2006.
[31] M. Naganuma, A. Saruwatari, S. Okamura, and H. Tamura,
“Turmeric and curcumin modulate the conjugation of 1-
naphthol in caco-2 cells,” Biological and Pharmaceutical
Bulletin, vol. 29, no. 7, pp. 1476–1479, 2006.
[32] C. L. Crespi, B. W. Penman, and M. Hu, “Development
of Caco-2 cells expressing high levels of cDNA-derived
cytochrome P4503A4,” Pharmaceutical Research, vol. 13, no.
11, pp. 1635–1641, 1996.
[33] M. Hu, Y. Li, C. M. Davitt et al., “Transport and metabolic
characterization of Caco-2 cells expressing CYP3A4 and
CYP3A4 plus oxidoreductase,” Pharmaceutical Research, vol.
16, no. 9, pp. 1352–1359, 1999.
[34] R. J. Price, M. P. Scott, A. M. Giddings et al., “Eﬀect
of butylated hydroxytoluene, curcumin, propyl gallate and
thiabendazole on cytochrome P450 forms in cultured human
hepatocytes,” Xenobiotica, vol. 38, no. 6, pp. 574–586, 2008.
[35] W. Zhang and L.-Y. Lim, “Eﬀects of spice constituents
on P-glycoprotein-mediated transport and CYP3A4-mediated
metabolism in vitro,” Drug Metabolism and Disposition, vol.
36, no. 7, pp. 1283–1290, 2008.
[36] S.P.Valentine, M.J.Le Nedelec, A.R.Menzies, M.J.Scandiyn,
M. G. Goodin, and R. J. Rosengren, “Curcumin modulates
drug metabolizing enzymes in the female Swiss Webster
mouse,” Life Sciences, vol. 78, pp. 2391–2398, 2006.
[37] M. F. Paine, W. W. Widmer, H. L. Hart et al.,
“A furanocoumarin-free grapefruit juice establishes
furanocoumarins as the mediators of the grapefruit juice-
felodipine interaction,” American Journal of Clinical Nutrition,
vol. 83, no. 5, pp. 1097–1105, 2006.
[38] D. I. Israel, M. G. Estolano, D. R. Galeazzi, and J. P. Whitlock,
“Superinduction of cytochrome P-450 gene transcription by
inhibition of protein synthesis in wild type and variant mouse
hepatoma cells,” The Journal of Biological Chemistry, vol. 260,
pp. 5648–5653, 1985.
[39] R.A.Sharma,H.R.McLelland,K.A.Hilletal.,“Pharmacody-
namic and pharmacokinetic study of oral Curcuma extract in
patients with colorectal cancer,” Clinical Cancer Research, vol.
7, no. 7, pp. 1894–1900, 2001.
[40] Y. Han, T. M. C. Tan, and L.-Y. Lim, “Eﬀects of capsaicin
on P-gp function and expression in Caco-2 cells,” Biochemical
Pharmacology, vol. 71, no. 12, pp. 1727–1734, 2006.